Analogues of Modafinil for treating sleep and attention disorders

Modafinil has attracted attention for the treatment of cognitive dysfunction in disorders such as attention-deficit/hyperactivity disorder (ADHD) as well as cocaine and methamphetamine dependence.   However, modafinil has relatively low affinity for binding to the dopamine transporter (DAT) to block dopamine reuptake, and is water-insoluble, thus requiring large doses to achieve pharmacological effects.Investigators at theNational Institute of Drug Abuse have synthesized a series of modafinil analogues that have higher affinity for the dopamine (DAT), serotonin (SERT) and/or norepinephrine (NET) transporters and improved water solubility.   These novel analogues present the advantage of higher potency, which may translate into lower effective doses and better bioavailability over modafinil.IC: NIDANIH Ref. No.: E-073-2013Advantages: Higher affinity for monoamine transporters (DAT, SERT, and NET) compared to modafinilAnalogues have lower effective dosesBetter bioavailability than modafinilImproved water solubility over modafinilApplications: Therapeutic agent for substance abuse (such as nicotine, cocaine, methamphetamine, opioids), for attention/cognitive disorders (such as ADHD), and for sleep disorders.Development Status: Discovery (Lead Identification)Updated On: Dec 20, 2017Provider Classifications: Publications: Patent Application: 14/772,486Patent Authority: U.S.Licensing Contacts: Lead Inventor: Inventor IC:...
Source: NIH OTT Licensing Opportunities - Category: Research Authors: Source Type: research